Skip to main content

Rheumatoid Arthritis

Targeting Obesity in Rheumatic Disease Patients Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese. https://t.co/OYtsbfJQ2e https://t.co/xEZI3mkY0q
Dr. John Cush @RheumNow( View Tweet )
Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and https://t.co/MaWx6AZ0JF
Dr. John Cush @RheumNow( View Tweet )
In 2021 the global rheumatoid arthritis market was valued at USD 22.77 billion and is expected to reach USD 33.30 billion by 2030. https://t.co/0vU6QP9JiG https://t.co/a8jXwk3KbK
Dr. John Cush @RheumNow( View Tweet )
MD Anderson Cancer Center study of 1991 RA pts w/ prostate, lung or colon cancer showed TNFi use in 1st 3yrs did NOT affect survival. Use of TNFi vs csDMARDs - nonsign lowering in CRCA (HR 0·72;0·43–1·21), Lung CA (0·70;0·49–1·00), Prostate CA (0·80;0·44–1·44) https://t.co/8zJ0OBWjbm
Dr. John Cush @RheumNow( View Tweet )
Researchers have developed a machine learning model capable of predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis. In the KURAMA cohort of 210 SN patients, 57 (27%) progressed to RA. The FNN model excelled with an AUC of 0.924 and 81% https://t.co/b8G2AzMZ7m
Dr. John Cush @RheumNow( View Tweet )
Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/VkPL7thzo8 https://t.co/h85iF6tIVk
Dr. John Cush @RheumNow( View Tweet )

Cancer Survival with TNF Inhibitors (3.28.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
Treating chronic inflammatory diseases with JAK inhibitors Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since their approval, the https://t.co/MUHLUbK5Ml
Dr. John Cush @RheumNow( View Tweet )
In 2021, the worldwide market for rheumatoid arthritis was valued at USD 22.77 billion and is projected to grow to USD 33.30 billion by 2030. https://t.co/HoUdQZfU8Q. https://t.co/Bcx9JMsavU
Dr. John Cush @RheumNow( View Tweet )
ACPA specificity and recognition motifs examined in 6,907 patients with RA from 5 Scandinavian cohorts. ACPA targeting non-glycine citrulline motifs assoc. more strongly w/ HLA-SE; ACPA to glycine citrulline motifs assoc. w/ smoking and IgA ACPA A&R https://t.co/PmKv3dZLc4 https://t.co/NdPG4Orfj4
ACR_Journals @ACR_Journals( View Tweet )

Worse Outcomes in HLA-B27+ JIA

MedPage Today

Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study.

Read Article

Predicting Premature Death with Multimorbidity

Machine learning (ML) models were used to predict premature death in inflammatory bowel disease (IBD) patients with multimorbidity, the co-occurrence of 2 or more chronic conditions. 

Read Article

Treating chronic inflammatory diseases with JAK inhibitors

Science Daily

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since their approval, the indications for these medical

Read Article
Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and https://t.co/3k6ZJTybAb
Dr. John Cush @RheumNow( View Tweet )

Autoimmune Disease Impact Report

Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: rheumatoid arthritis, multiple sclerosis,

Read Article
Veterans Admin (VA) EHR study of #RA-associated ILD (n 1047), matched 237 RA-ILD pts who Rx w/ TNFi vs 237 Rx w/ non-TNF biologics (mean age 68y; 92% male). Death & Resp hospitalisation were similar (adj HR 1·21, 1·27), as was mortality (1·15), Resp mortality (1·38) https://t.co/03LV5B4FSV
Dr. John Cush @RheumNow( View Tweet )
617 seropos ARTHRALGIA pts - 34% got inflamm. arthritis (avg time ~20mos). Arthritis risk factors: high ACPA (HR 4.7) or double positive(HR 6.8); 1st degree relative (1.5); intermittent Sxs(1.6); <12 mos Sxs (HR 0.71); AM stiff ≥1hr (1.6); joint swelling (1.5). IF > 2 https://t.co/tHL19ro5C8
Dr. John Cush @RheumNow( View Tweet )
Large GWAS study of smokers, shows that polygenic risk scores (PRS) for RA & ILD were assoc w/ their intended phenotypes in whites (OR 1.32 & 1.88, respectively) but no in blacks https://t.co/FflF2f1orq https://t.co/NlxcASrj9K
Dr. John Cush @RheumNow( View Tweet )
PAFLAR Guidelines for Polyarticular Juvenile Idiopathic Arthritis The Pediatric African League against Rheumatism (PAFLAR) initiative has published its guidelines for the diagnosis and treatment of polyarticular juvenile idiopathic arthritis (pJIA). https://t.co/4MbU8ZDLZf https://t.co/o3Oym9ff0f
Dr. John Cush @RheumNow( View Tweet )

ERA, APPs, & Alpha GAL (3.21.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  Listen in for 2 new case questions - Ask Cush Anything.

Read Article

Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis

A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and required major changes in treatment.

The aim of this study was to analyze disease activity and

Read Article
Spatial transcriptomic profiling on pre- and post-Rx synovial tissue Bxs from RA - Tx naive pts on DMARDs or adalimumab. Rx refractory patients had high expression of COMP, and fibroblast TGFβ signaling driving synovial tissue fibrosis https://t.co/1xFVvoddCD https://t.co/kYvhyX8VuS
Dr. John Cush @RheumNow( View Tweet )
RF levels may offer critical insights when treating RA. Learn why from two renowned rheumatologists. Sponsored by UCB https://t.co/yuUhmZR5bC https://t.co/Fsbu8Vztna
Dr. John Cush @RheumNow( View Tweet )
Channeling Bias and Cancer Risk with Biologic or Targeted Synthetic DMARDs A retrospective US administrative claims cohort study of Rheumatoid arthritis (RA) patients on tumor necrosis factor inhibitors (TNFis), non-TNFi biologics, or Janus kinase inhibitors (JAKis) found a… https://t.co/8jqJwkEbZF https://t.co/cQ9aheU5mc
Dr. John Cush @RheumNow( View Tweet )

PAFLAR Guidelines for Polyarticular Juvenile Idiopathic Arthritis

The Pediatric African League against Rheumatism (PAFLAR) initiative has published its guidelines for the diagnosis and treatment of polyarticular juvenile idiopathic arthritis (pJIA

Read Article
×